In vitro activity of RBx 7644 (ranbezolid) on biofilm producing bacteria

Mathur, Tarun; Bhateja, Pragya; Pandya, Manisha; Fatma, Tasneem; Rattan, Ashok

doi:10.1016/j.ijantimicag.2004.04.012

Cited by 20 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initial docking of linezolid produced conformation similar to that of the previously reported binding mode (25). As reported for the crystal structure, nucleotide residues G2061, A2451, A2503, U2504, G2505, and U2506 are important residues which are involved in interaction with linezolid (Fig.…”

Section: (D) Graphs Represent Means From Three Independent Experimensupporting

confidence: 80%

See 1 more Smart Citation

In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria

Barman

Kumar

Mathur

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Section: (D) Graphs Represent Means From Three Independent Experimensupporting

confidence: 80%

“…The effects of RBx 11760, linezolid, and vancomycin on biofilm production were assessed as described by previously with slight modifications (25). Briefly, the overnight growth of MRSE ATCC 35984 in TSB was diluted, adjusted to ϳ10 6 CFU/ml in TSB supplemented with 2% glucose, and incubated in polystyrene microtiter flat-bottom 96-well plates.…”

Section: Methodsmentioning

confidence: 99%

In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria

Barman

Kumar

Mathur

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…P. acnes biofilms were investigated using sintered glass beads (Siran carrier; SiKUG 023/02/300/A; SchottSchleiffer AG, Muttenz, Switzerland) using a protocol adapted from previous studies (22,42). The diameters of the beads ranged from 2 to 3 mm, and the porosity was 0.2 m 2 /g with a pore size of 60 to 300 m. For biofilm formation, beads were placed in rBHI, inoculated with 2 to 3 CFU of P. acnes, and incubated anaerobically at 37°C under static conditions for 3 h, 24 h, or 72 h.…”

Section: Study Organismmentioning

confidence: 99%

Role of Rifampin against Propionibacterium acnes Biofilm In Vitro and in an Experimental Foreign-Body Infection Model

Tafin

Corvec

Bétrisey

et al. 2012

Antimicrob Agents Chemother

166

108

View full text Add to dashboard Cite

c Propionibacterium acnes is an important cause of orthopedic-implant-associated infections, for which the optimal treatment has not yet been determined. We investigated the activity of rifampin, alone and in combination, against planktonic and biofilm P. acnes in vitro and in a foreign-body infection model. The MIC and the minimal bactericidal concentration (MBC) were 0.007 and 4 g/ml for rifampin, 1 and 4 g/ml for daptomycin, 1 and 8 g/ml for vancomycin, 1 and 2 g/ml for levofloxacin, 0.03 and 16 g/ml for penicillin G, 0.125 and 512 g/ml for clindamycin, and 0.25 and 32 g/ml for ceftriaxone. The P. acnes minimal biofilm eradication concentration (MBEC) was 16 g/ml for rifampin; 32 g/ml for penicillin G; 64 g/ml for daptomycin and ceftriaxone; and >128 g/ml for levofloxacin, vancomycin, and clindamycin. In the animal model, implants were infected by injection of 10 9 CFU P. acnes in cages. Antimicrobial activity on P. acnes was investigated in the cage fluid (planktonic form) and on explanted cages (biofilm form). The cure rates were 4% for daptomycin, 17% for vancomycin, 0% for levofloxacin, and 36% for rifampin. Rifampin cured 63% of the infected cages in combination with daptomycin, 46% with vancomycin, and 25% with levofloxacin. While all tested antimicrobials showed good activity against planktonic P. acnes, for eradication of biofilms, rifampin was needed. In combination with rifampin, daptomycin showed higher cure rates than with vancomycin in this foreign-body infection model.

show abstract

“…In addition, ranbezolid is the first oxazolidinone which showed similar activities against both gram-negative and gram-positive anaerobes (6,11). Further, ranbezolid exhibited significant in vitro activity against slime-producing staphylococci and mycobacteria (18,26). In this study, we have analyzed the properties of tion for local optimization of poses.…”

mentioning

confidence: 99%

Mode of Action of Ranbezolid against Staphylococci and Structural Modeling Studies of Its Interaction with Ribosomes

Kalia¹,

Miglani²,

Purnapatre³

et al. 2009

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Oxazolidinones are known to inhibit protein biosynthesis and act against a wide spectrum of gram-positive bacteria. A new investigational oxazolidinone, ranbezolid, inhibited bacterial protein synthesis in Staphylococcus aureus and Staphylococcus epidermidis. In S. epidermidis, ranbezolid showed inhibition of cell wall and lipid synthesis and a dose-dependent effect on membrane integrity. A kill-kinetics study showed that ranbezolid was bactericidal against S. epidermidis. In vitro translation of the luciferase gene done using bacterial and mammalian ribosomes indicated that ranbezolid specifically inhibited the bacterial ribosome. Molecular modeling studies revealed that both linezolid and ranbezolid fit in similar manners the active site of ribosomes, with total scores, i.e., theoretical binding affinities after consensus, of 5.2 and 6.9, respectively. The nitrofuran ring in ranbezolid is extended toward C2507, G2583, and U2584, and the nitro group forms a hydrogen bond from the base of G2583. The interaction of ranbezolid with the bacterial ribosomes clearly helps to elucidate its potent activity against the target pathogen.

show abstract

In vitro activity of RBx 7644 (ranbezolid) on biofilm producing bacteria

Cited by 20 publications

References 23 publications

In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria

In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria

Role of Rifampin against Propionibacterium acnes Biofilm In Vitro and in an Experimental Foreign-Body Infection Model

Mode of Action of Ranbezolid against Staphylococci and Structural Modeling Studies of Its Interaction with Ribosomes

Contact Info

Product

Resources

About